Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A Weak Link: Chinese Courts Reluctant To Grant Preliminary Injunctions In Pharma IP Cases

This article was originally published in PharmAsia News

Executive Summary

With a large number of pharma patents about to expire in China, hurdles to obtaining injunctive relief could be a huge problem, according to the EU Chamber of Commerce in China.

You may also be interested in...

Chinese Government Takes First Steps To De-link Indigenous Innovation And Procurement, But Industry Groups Wary

SHANGHAI - Months after pledging a policy change, China is finally taking steps to break ties between indigenous innovation and government procurement policies. The changes in policy, according to a report released by the U.S.-China Business Council, address growing concern among multinationals that procurement policies - an estimated $1 trillion market - are increasingly designed to shut them out

Insider Analysis From Morrison & Foerster LLP: China’s Bolar Exemption - Beware of the Uncertainties of Its Reach And Scope (Part 1 of 2)

By Janet Xiao, Morrison & Foerster LLP, Palo Alto and Michael Vella, Morrison & Foerster LLP, Shangha

What Lies Beneath China's Steep Price Cuts For New Drugs

Prices of  direct acting hepatitis C drugs are down by 85% in China, with cancer and antidiabetes therapy costs cut by 65% and drug makers are rushing to celebrate. Scrip delves into the considerations behind the low prices and whether industry's excitement is a bit premature. 


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts